- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02826278
Genitalia and Androgen in New Born Girls (VOGE)
Study Protocol: Reference Values for External Genitalia and Androgen Blood Level in New Born Girls
Normal values for female external genitalia size at birth, particularly clitoris and blood level of androgens are not well known. This study's aim is to collect normal values in 180 newborn girls of 24 to 41 weeks of pregnancy, and to build genitalia growth charts according to gestational age and birth weight.
The investigators will measure clitoris, genito-anal ratio using a small plastic caliper, at birth, and their evolution until Day 3 of life (if the child is still at the hospital).
The investigators also want to establish normal values of blood testosterone, 17-hydroxyprogesterone, delta4-androstenedione, 21-deoxycortisol, 11-deoxycortisol, deoxycorticosterone, corticosterone, dehydroepiandrostenedione, and dihydrotestosterone), using samples taken for systematic post natal screening of diseases (only in new born of 35 or more weeks of birth).
This is an observational prospective study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Bron, France
- Recruiting
- Hôpital Femme Mère Enfant
-
Contact:
- Claire-Lise Gay, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances. Dysmature children - i.e. those with a - 2DS birth weight or height at are not excluded.
Exclusion Criteria:
- Sexual development abnormality, diagnosed pre- or post- birth, endocrine disorder, obstetric trauma affecting genitalia, malformation syndrome, midline abnormalities, congenital cancer, maternal ovary or adrenal tumor diagnosed during pregnancy, mother or father's treatment during pregnancy likely to virilize the fetus, family history of congenital adrenal hyperplasia or neurofibromatosis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Healthy female newborns
Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
length of the clitoris
Time Frame: Day 1
|
The measurement is performed on the supine child, with flexed hips and knees retained by the nurse or the nursery nurse.
The clitoris will be delimited using cavernosa palpation.
The clitoris length will be measured from maxima lablias'root to the top of clitoris, excluding cutaneous cover.
Measurements are performed using an-8 cm plastic caliper.
|
Day 1
|
|
length of the clitoris
Time Frame: Day 3
|
The measurement is performed on the supine child, with flexed hips and knees retained by the nurse or the nursery nurse.
The clitoris will be delimited using cavernosa palpation.
The clitoris length will be measured from maxima lablias'root to the top of clitoris, excluding cutaneous cover.
Measurements are performed using an-8 cm plastic caliper
|
Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
clitoris width
Time Frame: Day 1
|
The clitoris will be measured at its base, using an-8 cm plastic caliper.
|
Day 1
|
|
clitoris width
Time Frame: Day 3
|
Measurement will be done if newborns stay at the hospital
|
Day 3
|
|
anogenital ratio
Time Frame: Day 1
|
The ano-genital ratio is the ratio between 1) the distance from anus center to the base of clitoris and 2) the distance from anus center and the posterior commissure of the vulva frenulum.
|
Day 1
|
|
anogenital ratio
Time Frame: Day 3
|
Measurement will be done if newborns stay at the hospital
|
Day 3
|
|
Blood level of testosterone
Time Frame: Day 3
|
This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
|
Day 3
|
|
Blood level of 17-hydroxyprogesterone
Time Frame: Day 3
|
This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
|
Day 3
|
|
Blood level of delta4-androstenedione
Time Frame: Day 3
|
This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
|
Day 3
|
|
Blood level of 21-deoxycortisol
Time Frame: Day 3
|
This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
|
Day 3
|
|
Blood level of corticosterone
Time Frame: Day 3
|
This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
|
Day 3
|
|
Blood level of dihydrotestosterone
Time Frame: Day 3
|
This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
|
Day 3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Claire-Lise GAY, MD, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 69HCL14_0451
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newborn Genitalia
-
Centro de Atenção ao Assoalho PélvicoCompletedDissatisfaction Appearance of the External Genitalia
-
ThuasneCompletedLymphedema of GenitaliaFrance
-
Meir Medical CenterWithdrawn
-
Johns Hopkins UniversityRecruitingWounds and Injuries | Amputation | Amputation, Traumatic | Urologic Surgical Procedures, Male | Amputation, Traumatic/Surgery | Penis/Transplantation | Penis/Surgery | Penis/Injuries | Congenital Anomaly, Male GenitaliaUnited States
-
Inonu UniversityCompletedNewborn | Newborn Sleep | Newborn StressTurkey
-
Universidad Autonoma de Nuevo LeonCompletedHospital Readmission | Newborn Morbidity | Newborn | Newborn Complication
-
Centre Hospitalier Sud FrancilienCompleted
-
Assumpta Solome NantumeDLR German Aerospace Center; Academic Model Providing Access to Healthcare...RecruitingNewborn Morbidity | Newborn ComplicationKenya
-
Basaksehir Cam & Sakura Şehir HospitalCompletedNewborn Cardiac Surgery | Newborn HemostasisTurkey
-
Centre Hospitalier Universitaire DijonNot yet recruitingMother Who Has Given Birth to a Singleton Newborn | Mother-newborn Dyad | Singleton NewbornFrance
Clinical Trials on External genitalia measurements in female newborns
-
University of PatrasRecruitingRespiratory Disease | Infant, Newborn, Disease | Respiratory Function TestsGreece
-
University of MilanASST Gaetano Pini-CTO; International Society of Arthroscopy, Knee Surgery and...RecruitingAugmentation | Arthroscopic Rotator Cuff Repair | Microfragmented Adipose TissueItaly